Login to Your Account



Search

Search results

Pharma: Clinic Roundup

• Pfizer Inc. , of New York, said a Phase IIIb withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy did not meet its primary endpoint, defined as the change in mean pain score ...

BioWorld Today - Staff - 2012-05-07 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• UCB SA , of Brussels, Belgium, reported post-hoc analyses of pivotal trials of Neupro (rotigotine transdermal system) in patients with restless legs syndrome (RLS)/Willis Ekbom disease, showing improvements with rotigotine vs. placebo in most of ...

BioWorld Today - Staff - 2012-04-26 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Pfizer Inc. , of New York, said it entered an agreement with Glaxosmithkline plc , of London, to explore the anticancer efficacy and safety of GSK’s trametinib (GSK1120212) combined with Pfizer’s palbociclib (PD-0332991) in a Phase I/II study ...

BioWorld Today - Staff - 2013-11-22 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• CSL Ltd. , of King of Prussia, Pa., presented data at the American Heart Association meeting in Dallas showing that CSL112 demonstrated favorable safety and tolerability when administered to patients with stable atherothrombotic disease and showed ...

BioWorld Today - Staff - 2013-11-21 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Boehringer Ingelheim GmbH , of Ingelheim, Germany, reported clinical results from a study of 145 healthy male volunteers showing that its fully humanized antibody fragment (Fab) rapidly reversed the anticoagulation effect of dabigatran, with onset ...

BioWorld Today - Staff - 2013-11-20 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Astrazeneca plc , of London, said it will conduct two new trials designed to build scientific understanding of Brilinta (ticagrelor) tablets in additional high-risk patient populations. One trial involves 9,600 patients who have experienced an acut ...

BioWorld Today - Staff - 2013-11-15 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Baxter International Inc. , of Deerfield, Ill., said it completed enrollment in its Phase III trial of BAX 855, an extended half-life recombinant Factor VIII treatment for hemophilia A. (BioWorld-Today-2013-11-14) ...

BioWorld Today - Staff - 2013-11-14 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Pfizer Inc. , of New York, said top-line results from a Phase IIb/IV study of Rapamune (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus (TAC)-based therapy to Rapamune three months to five months after transplant ...

BioWorld Today - Staff - 2013-11-11 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Boehringer Ingelheim GmbH , of Ingelheim, Germany, and Eli Lilly and Co. , of Indianapolis, reported data from a pooled analysis of 17 trials testing linagliptin in people with Type II diabetes and self-reported previous/current liver and biliar ...

BioWorld Today - Staff - 2013-11-08 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Shire plc , of Dublin, reported positive top-line results from two identically designed randomized placebo-controlled Phase III studies evaluating the efficacy and safety of Vyvanse (lisdexamfetamine dimesylate) capsules (CII) vs. placebo in adults ...

BioWorld Today - Staff - 2013-11-06 01:00 - 0 comments - 0 attachments